Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...
JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...
Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...
According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...
Analyst Carter Gould of Barclays maintained a Buy rating on AbbVie (ABBV – Research Report), retaining the price target of $212.00.
You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.
AbbVie (ABBV) has been one of the most searched ... When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its ...
Chicago Tribune on MSN13d
UChicago Medicine receives $75M donation for new cancer hospitalUniversity of Chicago Medicine has received a $75 million donation from the AbbVie Foundation to help it build its massive ...
The AbbVie Foundation, a nonprofit dedicated to addressing health inequities, has made a $75 million donation to the University of Chicago to support the construction of UChicago Medicine’s new cancer ...
AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback